Sodium valproate is indicated as an intravenous alternative in patients in whom oral administration of valproate products is temporarily not feasible in the following conditions:

• Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures

Seizure

Sodium valproate is intended for intravenous use only.

Epilepsy

• Complex Partial Seizures in Adults and Children 10 years of age or older: Initial dose is 10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to10 mg/kg/day to achieve optimal clinical response. Maximum recommended dose is 60 mg/kg/day.
• Simple and Complex Absence Seizures: Initial dose is 10 to 15 mg/kg/day, increasing at 1 week intervals by 5 to 10 mg/kg/day to achieve optimal clinical response. Maximum recommended dose is 60 mg/kg/day.

The common side effects may happen in people taking valproate. They're usually mild and go away by themselves-

• abdominal pain
• diarrhea
• dry or sore mouth, or swollen gums
• tremors
• unusual eye movements
• asthenia
• dizziness
• somnolence
• headache
• weight gain
• alopecia
• dymenorrhea

Abdominal Pain	Diarrhea	Dry Mouth
Tremor (Shaking)	Asthenia	Dizziness

• Hepatotoxicity: Evaluate high risk populations and monitor serum liver tests
• Birth defects, decreased IQ, and neurodevelopmental disorders following in utero exposure: Should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant or to treat a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable 
• Pancreatitis: Sodium Valproate should generally be discontinued.
• Bleeding and other hematopoietic disorders: Monitor platelet counts and coagulation tests.
• Hyperammonemia and hyper ammonemic encephalopathy: Measure ammonia level if unexplained lethargy and vomiting or changes in mental status, and also with concomitant topiramate use; consider discontinuation of valproate therapy.
• Hypothermia: Hypothermia has been reported during valproate therapy with or without associated hyperammonemia. This adverse reaction can also occur in patients using concomitant topiramate.
• Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan hypersensitivity reaction; discontinue Sodium Valproate.
• Somnolence in the elderly can occur. Sodium Valproate dosage should be increased slowly and with regular monitoring for fluid and nutritional intake.